Analysts Expect Emergent Biosolutions Inc (EBS) Will Post Earnings of $0.54 Per Share
Wall Street brokerages expect Emergent Biosolutions Inc (NYSE:EBS) to report earnings of $0.54 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Emergent Biosolutions’ earnings, with the lowest EPS estimate coming in at $0.52 and the highest estimate coming in at $0.56. Emergent Biosolutions posted earnings of $0.74 per share in the same quarter last year, which indicates a negative year over year growth rate of 27%. The company is scheduled to announce its next quarterly earnings report on Thursday, February 28th.
According to Zacks, analysts expect that Emergent Biosolutions will report full year earnings of $1.98 per share for the current financial year, with EPS estimates ranging from $1.29 to $2.18. For the next financial year, analysts forecast that the firm will report earnings of $3.03 per share, with EPS estimates ranging from $1.50 to $3.74. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Emergent Biosolutions.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.07). The business had revenue of $173.70 million for the quarter, compared to the consensus estimate of $185.16 million. Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The firm’s revenue for the quarter was up 16.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.73 EPS.
EBS traded up $0.04 during midday trading on Tuesday, reaching $69.74. 354,100 shares of the company’s stock were exchanged, compared to its average volume of 344,710. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of 36.71, a P/E/G ratio of 1.80 and a beta of 1.27. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01. Emergent Biosolutions has a one year low of $37.89 and a one year high of $71.77.
In related news, CEO Daniel Abdun-Nabi sold 28,220 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $65.00, for a total value of $1,834,300.00. Following the completion of the sale, the chief executive officer now owns 194,787 shares of the company’s stock, valued at $12,661,155. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Kathryn C. Zoon sold 4,242 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $69.74, for a total transaction of $295,837.08. Following the completion of the sale, the director now directly owns 33,972 shares of the company’s stock, valued at approximately $2,369,207.28. The disclosure for this sale can be found here. Insiders sold 155,732 shares of company stock valued at $9,608,408 in the last quarter. 13.40% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of EBS. BlackRock Inc. increased its holdings in shares of Emergent Biosolutions by 18.2% in the third quarter. BlackRock Inc. now owns 6,350,905 shares of the biopharmaceutical company’s stock valued at $418,078,000 after purchasing an additional 978,194 shares in the last quarter. Matarin Capital Management LLC acquired a new stake in shares of Emergent Biosolutions in the third quarter valued at approximately $24,553,000. Neuberger Berman Group LLC acquired a new stake in shares of Emergent Biosolutions in the third quarter valued at approximately $22,064,000. Renaissance Technologies LLC increased its holdings in shares of Emergent Biosolutions by 10.6% in the second quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock valued at $104,338,000 after purchasing an additional 198,600 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Emergent Biosolutions by 192.7% in the second quarter. FMR LLC now owns 290,507 shares of the biopharmaceutical company’s stock valued at $14,668,000 after purchasing an additional 191,248 shares in the last quarter. 82.23% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Featured Story: Price to Earnings Ratio (PE) Basics
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.